You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

To UNSUBSCRIBE from this list, or change your e-mail address, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

Please do not reply to this message.
_______________________________________________

The Food and Drug Administration (FDA), on July 7, 2005, granted tentative approval for a generic combination drug product consisting of lamivudine and zidovudine, manufactured by Aurobindo Pharma LTD. Hyderabad, India.

FDA tentative approval means that the product meets all of FDA's quality, safety and efficacy standards, but existing patents and/or exclusivity prevent marketing of the product in the U.S.  Tentative approval by FDA, however, makes this Aurobindo generic product available for consideration for purchase and use outside the United States under the President's Emergency Plan for AIDS Relief (PEPFAR).

The Aurobindo lamivudine/zidovudine combination product is a generic version of the U.S. approved Combivir lamivudine/zidovudine combination manufactured by GlaxoSmithKline.

Lamivudine and Zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing.  This combination antiretroviral drug is intended to be used with other antiretroviral agents in the treatment of HIV-1 infection.

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html